Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies

Alette Ruarus, Laurien Vroomen, Robbert Puijk, Hester Scheffer, Martijn Meijerink, Alette Ruarus, Laurien Vroomen, Robbert Puijk, Hester Scheffer, Martijn Meijerink

Abstract

Pancreatic cancer is typically characterized by its aggressive tumor growth and dismal prognosis. Approximately 30% of patients with pancreatic cancer present with locally advanced disease, broadly defined as having a tumor-to-artery interface >180°, having an unreconstructable portal vein or superior mesenteric vein and no signs of metastatic disease. These patients are currently designated to palliative systemic chemotherapy, though median overall survival remains poor (approximately 11 months). Therefore, several innovative local therapies have been investigated as new treatment options for locally advanced pancreatic cancer (LAPC). This article provides an overview of available data with regard to morbidity and oncological outcome of novel local therapies for LAPC.

Keywords: local ablative therapies; locally advanced pancreatic cancer (LAPC); pancreatic cancer.

Conflict of interest statement

M.M. is a paid consultant for AngioDynamics. The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Median overall survival in months after RFA*, SBRT and IRE per number of patients per study. * All procedures in all studies performed at one single center: the University of Verona Hospital Trust; given the overlapping date ranges patient data are likely (partially) re-reported.

References

    1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155.
    1. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017;67:7–30. doi: 10.3322/caac.21387.
    1. Kamisawa T., Wood L.D., Itoi T., Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. doi: 10.1016/S0140-6736(16)00141-0.
    1. Ducreux M., Cuhna A.S., Caramella C., Hollebecque A., Burtin P., Goere D., Seufferlein T., Haustermans K., Van Laethem J.L., Conroy T., et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26(Suppl. S5):56–68. doi: 10.1093/annonc/mdv295.
    1. Gurusamy K.S., Kumar S., Davidson B.R., Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst. Rev. 2014 doi: 10.1002/14651858.CD010244.pub2.
    1. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Ritchey J., Stewart A.K., Winchester D.P., Talamonti M.S. Validation of the 6th edition ajcc pancreatic cancer staging system: Report from the national cancer database. Cancer. 2007;110:738–744. doi: 10.1002/cncr.22852.
    1. Conroy T., Desseigne F., Ychou M., Bouche O., Guimbaud R., Becouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardiere C., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011;364:1817–1825. doi: 10.1056/NEJMoa1011923.
    1. Sohal D.P., Mangu P.B., Khorana A.A., Shah M.A., Philip P.A., O’Reilly E.M., Uronis H.E., Ramanathan R.K., Crane C.H., Engebretson A., et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2016;34:2784–2796. doi: 10.1200/JCO.2016.67.1412.
    1. Khorana A.A., Mangu P.B., Berlin J., Engebretson A., Hong T.S., Maitra A., Mohile S.G., Mumber M., Schulick R., Shapiro M., et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2017;35:2324–2328. doi: 10.1200/JCO.2017.72.4948.
    1. Ahmed M., Brace C.L., Lee F.T., Jr., Goldberg S.N. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351–369. doi: 10.1148/radiol.10081634.
    1. Carrafiello G., Ierardi A.M., Fontana F., Petrillo M., Floridi C., Lucchina N., Cuffari S., Dionigi G., Rotondo A., Fugazzola C. Microwave ablation of pancreatic head cancer: Safety and efficacy. J. Vasc. Interv. Radiol. 2013;24:1513–1520. doi: 10.1016/j.jvir.2013.07.005.
    1. Cazzato R.L., Garnon J., Ramamurthy N., Koch G., Tsoumakidou G., Caudrelier J., Arrigoni F., Zugaro L., Barile A., Masciocchi C., et al. Percutaneous image-guided cryoablation: Current applications and results in the oncologic field. Med. Oncol. 2016;33:140. doi: 10.1007/s12032-016-0848-3.
    1. Dubinsky T.J., Cuevas C., Dighe M.K., Kolokythas O., Hwang J.H. High-intensity focused ultrasound: Current potential and oncologic applications. AJR Am. J. Roentgenol. 2008;190:191–199. doi: 10.2214/AJR.07.2671.
    1. Chauffert B., Mornex F., Bonnetain F., Rougier P., Mariette C., Bouche O., Bosset J.F., Aparicio T., Mineur L., Azzedine A., et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann. Oncol. 2008;19:1592–1599.
    1. Hammel P., Huguet F., van Laethem J.L., Goldstein D., Glimelius B., Artru P., Borbath I., Bouche O., Shannon J., Andre T., et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA. 2016;315:1844–1853. doi: 10.1001/jama.2016.4324.
    1. Loehrer P.J., Sr., Feng Y., Cardenes H., Wagner L., Brell J.M., Cella D., Flynn P., Ramanathan R.K., Crane C.H., Alberts S.R., et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: An Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 2011;29:4105–4112. doi: 10.1200/JCO.2011.34.8904.
    1. Xu K., Niu L., Mu F., Hu Y. Cryosurgery in combination with brachytherapy of iodine-125 seeds for pancreatic cancer. Gland Surg. 2013;2:91–99.
    1. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer. 2003;3:380–387. doi: 10.1038/nrc1071.
    1. Scheffer H.J., Nielsen K., van Tilborg A.A., Vieveen J.M., Bouwman R.A., Kazemier G., Niessen H.W., Meijer S., van Kuijk C., van den Tol M.P., et al. Ablation of colorectal liver metastases by irreversible electroporation: Results of the COLDFIRE-I ablate-and-resect study. Eur. Radiol. 2014;24:2467–2475. doi: 10.1007/s00330-014-3259-x.
    1. Bimonte S., Leongito M., Granata V., Barbieri A., Del Vecchio V., Falco M., Nasto A., Albino V., Piccirillo M., Palaia R., et al. Electrochemotherapy in pancreatic adenocarcinoma treatment: Pre-clinical and clinical studies. Radiol. Oncol. 2016;50:14–20.
    1. Cantore M., Girelli R., Mambrini A., Frigerio I., Boz G., Salvia R., Giardino A., Orlandi M., Auriemma A., Bassi C. Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma. Br. J. Surg. 2012;99:1083–1088. doi: 10.1002/bjs.8789.
    1. Girelli R., Frigerio I., Giardino A., Regi P., Gobbo S., Malleo G., Salvia R., Bassi C. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch. Surg. 2013;398:63–69. doi: 10.1007/s00423-012-1011-z.
    1. Girelli R., Frigerio I., Salvia R., Barbi E., Tinazzi Martini P., Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br. J. Surg. 2010;97:220–225. doi: 10.1002/bjs.6800.
    1. D’Onofrio M., Crosara S., De Robertis R., Butturini G., Salvia R., Paiella S., Bassi C., Mucelli R.P. Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results. Technol. Cancer Res. Treat. 2017;16:285–294. doi: 10.1177/1533034616649292.
    1. Frigerio I., Girelli R., Giardino A., Regi P., Salvia R., Bassi C. Short term chemotherapy followed by radiofrequency ablation in stage III pancreatic cancer: Results from a single center. J. Hepatobiliary Pancreat. Sci. 2013;20:574–577. doi: 10.1007/s00534-013-0613-3.
    1. Paiella S., Malleo G., Cataldo I., Gasparini C., De Pastena M., De Marchi G., Marchegiani G., Rusev B., Scarpa A., Girelli R., et al. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Langenbecks Arch. Surg. 2017 doi: 10.1007/s00423-017-1627-0.
    1. Lygidakis N.J., Sharma S.K., Papastratis P., Zivanovic V., Kefalourous H., Koshariya M., Lintzeris I., Porfiris T., Koutsiouroumba D. Microwave ablation in locally advanced pancreatic carcinoma—A new look. Hepatogastroenterology. 2007;54:1305–1310.
    1. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., et al. New response evaluation criteria in solid tumours: Revised recist guideline (version 1.1) Eur J. Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Li J., Chen X., Yang H., Wang X., Yuan D., Zeng Y., Wen T., Yan L., Li B. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: A retrospective study of 142 patients. Postgrad. Med. J. 2011;87:89–95. doi: 10.1136/pgmj.2010.098350.
    1. Song Z.G., Hao J.H., Gao S., Gao C.T., Tang Y., Liu J.C. The outcome of cryoablation in treating advanced pancreatic cancer: A comparison with palliative bypass surgery alone. J. Dig. Dis. 2014;15:561–569. doi: 10.1111/1751-2980.12170.
    1. Gao H.F., Wang K., Meng Z.Q., Chen Z., Lin J.H., Zhou Z.H., Wang P., Shi W.D., Sheng Y.H. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology. 2013;60:1906–1910.
    1. Li Y.J., Huang G.L., Sun X.L., Zhao X.C., Li Z.G. The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World J. Surg. Oncol. 2016;14:60. doi: 10.1186/s12957-016-0809-5.
    1. Sofuni A., Moriyasu F., Sano T., Itokawa F., Tsuchiya T., Kurihara T., Ishii K., Tsuji S., Ikeuchi N., Tanaka R., et al. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J. Gastroenterol. 2014;20:9570–9577. doi: 10.3748/wjg.v20.i28.9570.
    1. Sung H.Y., Jung S.E., Cho S.H., Zhou K., Han J.Y., Han S.T., Kim J.I., Kim J.K., Choi J.Y., Yoon S.K., et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011;40:1080–1086. doi: 10.1097/MPA.0b013e31821fde24.
    1. Wang K., Chen Z., Meng Z., Lin J., Zhou Z., Wang P., Chen L., Liu L. Analgesic effect of high intensity focused ultrasound therapy for unresectable pancreatic cancer. Int. J. Hyperther. 2011;27:101–107. doi: 10.3109/02656736.2010.525588.
    1. Zhao H., Yang G., Wang D., Yu X., Zhang Y., Zhu J., Ji Y., Zhong B., Zhao W., Yang Z., et al. Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer. Anticancer Drugs. 2010;21:447–452. doi: 10.1097/CAD.0b013e32833641a7.
    1. Ning Z.Y., Cheng C.S., Xie J., Chen Q.W., Xu L.T., Zhuang L.P., Zhang C.Y., Song L.B., Shi W.D., Zhu X.Y., et al. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Discov. Med. 2016;21:435–445.
    1. Shi Y., Ying X., Hu X., Shen H. Pain management of pancreatic cancer patients with high-intensity focused ultrasound therapy. Pak. J. Pharm. Sci. 2017;30:303–307.
    1. Xiong L.L., Hwang J.H., Huang X.B., Yao S.S., He C.J., Ge X.H., Ge H.Y., Wang X.F. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer. JOP. 2009;10:123–129.
    1. Zhao J., Zhao F., Shi Y., Deng Y., Hu X., Shen H. The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer. J. Cancer Res. Clin. Oncol. 2017 doi: 10.1007/s00432-017-2459-6.
    1. Wang K., Zhu H., Meng Z., Chen Z., Lin J., Shen Y., Gao H. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Onkologie. 2013;36:88–92. doi: 10.1159/000348530.
    1. Vidal-Jove J., Perich E., Del Castillo M.A. Ultrasound Guided High Intensity Focused Ultrasound for malignant tumors: The Spanish experience of survival advantage in stage III and IV pancreatic cancer. Ultrason. Sonochem. 2015;27:703–706. doi: 10.1016/j.ultsonch.2015.05.026.
    1. Comito T., Cozzi L., Clerici E., Franzese C., Tozzi A., Iftode C., Navarria P., D’Agostino G., Rimassa L., Carnaghi C., et al. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. Technol. Cancer Res. Treat. 2017;16:295–301. doi: 10.1177/1533034616650778.
    1. Dholakia A.S., Chaudhry M., Leal J.P., Chang D.T., Raman S.P., Hacker-Prietz A., Su Z., Pai J., Oteiza K.E., Griffith M.E., et al. Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 2014;89:539–546. doi: 10.1016/j.ijrobp.2014.02.031.
    1. Gurka M.K., Collins S.P., Slack R., Tse G., Charabaty A., Ley L., Berzcel L., Lei S., Suy S., Haddad N., et al. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: A pilot trial demonstrating safety. Radiat. Oncol. 2013;8:44. doi: 10.1186/1748-717X-8-44.
    1. Herman J.M., Chang D.T., Goodman K.A., Dholakia A.S., Raman S.P., Hacker-Prietz A., Iacobuzio-Donahue C.A., Griffith M.E., Pawlik T.M., Pai J.S., et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121:1128–1137. doi: 10.1002/cncr.29161.
    1. Koong A.C., Le Q.T., Ho A., Fong B., Fisher G., Cho C., Ford J., Poen J., Gibbs I.C., Mehta V.K., et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2004;58:1017–1021. doi: 10.1016/j.ijrobp.2003.11.004.
    1. Polistina F., Costantin G., Casamassima F., Francescon P., Guglielmi R., Panizzoni G., Febbraro A., Ambrosino G. Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann. Surg. Oncol. 2010;17:2092–2101. doi: 10.1245/s10434-010-1019-y.
    1. Schellenberg D., Goodman K.A., Lee F., Chang S., Kuo T., Ford J.M., Fisher G.A., Quon A., Desser T.S., Norton J., et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008;72:678–686. doi: 10.1016/j.ijrobp.2008.01.051.
    1. Schellenberg D., Kim J., Christman-Skieller C., Chun C.L., Columbo L.A., Ford J.M., Fisher G.A., Kunz P.L., Van Dam J., Quon A., et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011;81:181–188. doi: 10.1016/j.ijrobp.2010.05.006.
    1. Tozzi A., Comito T., Alongi F., Navarria P., Iftode C., Mancosu P., Reggiori G., Clerici E., Rimassa L., Zerbi A., et al. SBRT in unresectable advanced pancreatic cancer: Preliminary results of a mono-institutional experience. Radiat. Oncol. 2013;8:148. doi: 10.1186/1748-717X-8-148.
    1. Alagappan M., Pollom E.L., von Eyben R., Kozak M.M., Aggarwal S., Poultsides G.A., Koong A.C., Chang D.T. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Am. J. Clin. Oncol. 2016 doi: 10.1097/COC.0000000000000263.
    1. Chang D.T., Schellenberg D., Shen J., Kim J., Goodman K.A., Fisher G.A., Ford J.M., Desser T., Quon A., Koong A.C. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115:665–672. doi: 10.1002/cncr.24059.
    1. Chuong M.D., Springett G.M., Freilich J.M., Park C.K., Weber J.M., Mellon E.A., Hodul P.J., Malafa M.P., Meredith K.L., Hoffe S.E., et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int. J. Radiat. Oncol. Biol. Phys. 2013;86:516–522. doi: 10.1016/j.ijrobp.2013.02.022.
    1. Mahadevan A., Jain S., Goldstein M., Miksad R., Pleskow D., Sawhney M., Brennan D., Callery M., Vollmer C. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010;78:735–742. doi: 10.1016/j.ijrobp.2009.08.046.
    1. Mahadevan A., Miksad R., Goldstein M., Sullivan R., Bullock A., Buchbinder E., Pleskow D., Sawhney M., Kent T., Vollmer C., et al. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int. J. Radiat. Oncol. Biol. Phys. 2011;81:e615–e622. doi: 10.1016/j.ijrobp.2011.04.045.
    1. Mellon E.A., Hoffe S.E., Springett G.M., Frakes J.M., Strom T.J., Hodul P.J., Malafa M.P., Chuong M.D., Shridhar R. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:979–985. doi: 10.3109/0284186X.2015.1004367.
    1. Moningi S., Dholakia A.S., Raman S.P., Blackford A., Cameron J.L., Le D.T., De Jesus-Acosta A.M., Hacker-Prietz A., Rosati L.M., Assadi R.K., et al. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann. Surg. Oncol. 2015;22:2352–2358. doi: 10.1245/s10434-014-4274-5.
    1. Rwigema J.C., Parikh S.D., Heron D.E., Howell M., Zeh H., Moser A.J., Bahary N., Quinn A., Burton S.A. Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas. Am. J. Clin. Oncol. 2011;34:63–69. doi: 10.1097/COC.0b013e3181d270b4.
    1. Song Y., Yuan Z., Li F., Dong Y., Zhuang H., Wang J., Chen H., Wang P. Analysis of clinical efficacy of CyberKnife® treatment for locally advanced pancreatic cancer. Onco Targets Ther. 2015;8:1427–1431. doi: 10.2147/OTT.S81939.
    1. Zhu X., Li F., Ju X., Cao F., Cao Y., Fang F., Qing S., Shen Y., Jia Z., Zhang H. Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Cancer Med. 2017;6:2263–2270. doi: 10.1002/cam4.1164.
    1. Wang J., Jiang Y., Li J., Tian S., Ran W., Xiu D. Intraoperative ultrasound-guided iodine-125 seed implantation for unresectable pancreatic carcinoma. J. Exp. Clin. Cancer Res. 2009;28:88. doi: 10.1186/1756-9966-28-88.
    1. Wang H., Wang J., Jiang Y., Li J., Tian S., Ran W., Xiu D., Gao Y. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J. Exp. Clin. Cancer Res. 2013;32:106. doi: 10.1186/1756-9966-32-106.
    1. Xu K.C., Niu L.Z., Hu Y.Z., He W.B., He Y.S., Li Y.F., Zuo J.S. A pilot study on combination of cryosurgery and (125)iodine seed implantation for treatment of locally advanced pancreatic cancer. World J. Gastroenterol. 2008;14:1603–1611. doi: 10.3748/wjg.14.1603.
    1. Xu K.C., Niu L.Z., Hu Y.Z., He W.B., He Y.S., Zuo J.S. Cryosurgery with combination of (125)iodine seed implantation for the treatment of locally advanced pancreatic cancer. J. Dig. Dis. 2008;9:32–40. doi: 10.1111/j.1443-9573.2007.00322.x.
    1. Zou Y.P., Li W.M., Zheng F., Li F.C., Huang H., Du J.D., Liu H.R. Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J. Gastroenterol. 2010;16:5104–5110. doi: 10.3748/wjg.v16.i40.5104.
    1. Kluger M.D., Epelboym I., Schrope B.A., Mahendraraj K., Hecht E.M., Susman J., Weintraub J.L., Chabot J.A. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients. Ann. Surg. Oncol. 2016;23:1736–1743. doi: 10.1245/s10434-015-5034-x.
    1. Martin R.C., Kwon D., Chalikonda S., Sellers M., Kotz E., Scoggins C., McMasters K.M., Watkins K. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: Safety and efficacy. Ann. Surg. 2015;262:486–494. doi: 10.1097/SLA.0000000000001441.
    1. Martin R.C., McFarland K., Ellis S., Velanovich V. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J. Am. Coll. Surg. 2012;215:361–369. doi: 10.1016/j.jamcollsurg.2012.05.021.
    1. Martin R.C., McFarland K., Ellis S., Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: Potential improved overall survival. Ann. Surg. Oncol. 2013;20(Suppl. S3):S443–S449. doi: 10.1245/s10434-012-2736-1.
    1. Belfiore G., Belfiore M.P., Reginelli A., Capasso R., Romano F., Ianniello G.P., Cappabianca S., Brunese L. Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer. Med. Oncol. 2017;34:38. doi: 10.1007/s12032-017-0887-4.
    1. Dunki-Jacobs E.M., Philips P., Martin R.C. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J. Am. Coll. Surg. 2014;218:179–187. doi: 10.1016/j.jamcollsurg.2013.10.013.
    1. Lambert L., Horejs J., Krska Z., Hoskovec D., Petruzelka L., Krechler T., Kriz P., Briza J. Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: General hospital cancer center experience. Neoplasma. 2016;63:269–273. doi: 10.4149/213_150611N326.
    1. Mansson C., Brahmstaedt R., Nilsson A., Nygren P., Karlson B.M. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur. J. Surg. Oncol. 2016;42:1401–1406. doi: 10.1016/j.ejso.2016.01.024.
    1. Narayanan G., Hosein P.J., Beulaygue I.C., Froud T., Scheffer H.J., Venkat S.R., Echenique A.M., Hevert E.C., Livingstone A.S., Rocha-Lima C.M., et al. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. J. Vasc. Interv. Radiol. 2017;28:342–348. doi: 10.1016/j.jvir.2016.10.023.
    1. Paiella S., Butturini G., Frigerio I., Salvia R., Armatura G., Bacchion M., Fontana M., D’Onofrio M., Martone E., Bassi C. Safety and feasibility of Irreversible Electroporation (IRE) in patients with locally advanced pancreatic cancer: Results of a prospective study. Dig. Surg. 2015;32:90–97. doi: 10.1159/000375323.
    1. Scheffer H.J., Vroomen L.G., de Jong M.C., Melenhorst M.C., Zonderhuis B.M., Daams F., Vogel J.A., Besselink M.G., van Kuijk C., Witvliet J., et al. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study. Radiology. 2017;282:585–597. doi: 10.1148/radiol.2016152835.
    1. Vogel J.A., Rombouts S.J., de Rooij T., van Delden O.M., Dijkgraaf M.G., van Gulik T.M., van Hooft J.E., van Laarhoven H.W., Martin R.C., Schoorlemmer A., et al. Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Ann. Surg. Oncol. 2017;24:2734–2743. doi: 10.1245/s10434-017-5900-9.
    1. Yan L., Chen Y.L., Su M., Liu T., Xu K., Liang F., Gu W.Q., Lu S.C. A Single-institution Experience with Open Irreversible Electroporation for Locally Advanced Pancreatic Carcinoma. Chin. Med. J. Engl. 2016;129:2920–2925.
    1. Zhang Y., Shi J., Zeng J., Alnagger M., Zhou L., Fang G., Long X., Pan Z., Li Y., Chen J., et al. Percutaneous Irreversible Electroporation for Ablation of Locally Advanced Pancreatic Cancer: Experience From a Chinese Institution. Pancreas. 2017;46:e12–e14. doi: 10.1097/MPA.0000000000000703.
    1. Belfiore M.P., Ronza F.M., Romano F., Ianniello G.P., De Lucia G., Gallo C., Marsicano C., Di Gennaro T.L., Belfiore G. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience. Int. J. Surg. 2015;21(Suppl. S1):S34–S39. doi: 10.1016/j.ijsu.2015.06.049.
    1. Huggett M.T., Jermyn M., Gillams A., Illing R., Mosse S., Novelli M., Kent E., Bown S.G., Hasan T., Pogue B.W., et al. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br. J. Cancer. 2014;110:1698–1704. doi: 10.1038/bjc.2014.95.
    1. Bown S.G., Rogowska A.Z., Whitelaw D.E., Lees W.R., Lovat L.B., Ripley P., Jones L., Wyld P., Gillams A., Hatfield A.W. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549–557. doi: 10.1136/gut.50.4.549.
    1. Granata V., Fusco R., Piccirillo M., Palaia R., Petrillo A., Lastoria S., Izzo F. Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. Int. J. Surg. 2015;18:230–236. doi: 10.1016/j.ijsu.2015.04.055.
    1. Granata V., Fusco R., Setola S.V., Piccirillo M., Leongito M., Palaia R., Granata F., Lastoria S., Izzo F., Petrillo A. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J. Gastroenterol. 2017;23:4767–4778. doi: 10.3748/wjg.v23.i26.4767.
    1. Tempero M.A., Malafa M.P., Al-Hawary M., Asbun H., Bain A., Behrman S.W., Benson A.B., Binder E., Cardin D.B., Cha C., et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2017;15:1028–1061. doi: 10.6004/jnccn.2017.0131.
    1. Giardino A., Girelli R., Frigerio I., Regi P., Cantore M., Alessandra A., Lusenti A., Salvia R., Bassi C., Pederzoli P. Triple approach strategy for patients with locally advanced pancreatic carcinoma. HPB Oxford. 2013;15:623–627. doi: 10.1111/hpb.12027.
    1. Varadhachary G.R., Tamm E.P., Abbruzzese J.L., Xiong H.Q., Crane C.H., Wang H., Lee J.E., Pisters P.W., Evans D.B., Wolff R.A. Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy. Ann. Surg. Oncol. 2006;13:1035–1046. doi: 10.1245/ASO.2006.08.011.
    1. de Geus S.W.L., Eskander M.F., Kasumova G.G., Ng S.C., Kent T.S., Mancias J.D., Callery M.P., Mahadevan A., Tseng J.F. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review. Cancer. 2017 doi: 10.1002/cncr.30856.
    1. Petrelli F., Comito T., Ghidini A., Torri V., Scorsetti M., Barni S. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int. J. Radiat. Oncol. Biol. Phys. 2017;97:313–322. doi: 10.1016/j.ijrobp.2016.10.030.
    1. Bohoudi O., Bruynzeel A.M.E., Senan S., Cuijpers J.P., Slotman B.J., Lagerwaard F.J., Palacios M.A. Fast and robust online adaptive planning in stereotactic MR-guided adaptive radiation therapy (SMART) for pancreatic cancer. Radiother. Oncol. 2017 doi: 10.1016/j.radonc.2017.07.028.
    1. Strunk H.M., Henseler J., Rauch M., Mucke M., Kukuk G., Cuhls H., Radbruch L., Zhang L., Schild H.H., Marinova M. Clinical Use of High-Intensity Focused Ultrasound (HIFU) for Tumor and Pain Reduction in Advanced Pancreatic Cancer. Rofo. 2016;188:662–670. doi: 10.1055/s-0042-105517.
    1. Vroomen L., Petre E.N., Cornelis F.H., Solomon S.B., Srimathveeravalli G. Irreversible electroporation and thermal ablation of tumors in the liver, lung, kidney and bone: What are the differences? Diagn. Interv. Imaging. 2017;98:609–617. doi: 10.1016/j.diii.2017.07.007.
    1. Ansari D., Kristoffersson S., Andersson R., Bergenfeldt M. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: A systematic review of safety and efficacy. Scand. J. Gastroenterol. 2017 doi: 10.1080/00365521.2017.1346705.
    1. Martin R.C., Durham A.N., Besselink M.G., Iannitti D., Weiss M.J., Wolfgang C.L., Huang K.W. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. J. Surg. Oncol. 2016;114:865–871. doi: 10.1002/jso.24404.
    1. Giardino A., Innamorati G., Ugel S., Perbellini O., Girelli R., Frigerio I., Regi P., Scopelliti F., Butturini G., Paiella S., et al. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Pancreatology. 2017 doi: 10.1016/j.pan.2017.09.008.
    1. Niu L., Chen J., He L., Liao M., Yuan Y., Zeng J., Li J., Zuo J., Xu K. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer. Pancreas. 2013;42:1143–1149. doi: 10.1097/MPA.0b013e3182965dde.
    1. Rovere-Querini P., Manfredi A.A. Tumor destruction and in situ delivery of antigen presenting cells promote anti-neoplastic immune responses: Implications for the immunotherapy of pancreatic cancer. JOP. 2004;5:308–314.
    1. Vatner R.E., Cooper B.T., Vanpouille-Box C., Demaria S., Formenti S.C. Combinations of immunotherapy and radiation in cancer therapy. Front. Oncol. 2014;4:325. doi: 10.3389/fonc.2014.00325.
    1. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet. 2011;378:607–620. doi: 10.1016/S0140-6736(10)62307-0.
    1. Kanda M., Matthaei H., Wu J., Hong S.M., Yu J., Borges M., Hruban R.H., Maitra A., Kinzler K., Vogelstein B., et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730–733. doi: 10.1053/j.gastro.2011.12.042.
    1. Maitra A., Adsay N.V., Argani P., Iacobuzio-Donahue C., De Marzo A., Cameron J.L., Yeo C.J., Hruban R.H. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod. Pathol. 2003;16:902–912. doi: 10.1097/01.MP.0000086072.56290.FB.
    1. Noonan A.M., Farren M.R., Geyer S.M., Huang Y., Tahiri S., Ahn D., Mikhail S., Ciombor K.K., Pant S., Aparo S., et al. Randomized phase 2 trial of the oncolytic virus pelareorep (reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma. Mol. Ther. 2016;24:1150–1158. doi: 10.1038/mt.2016.66.
    1. Sze D.Y., Reid T.R., Rose S.C. Oncolytic virotherapy. J. Vasc. Interv. Radiol. 2013;24:1115–1122. doi: 10.1016/j.jvir.2013.05.040.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren